Half-year report · Q2
6095.TEDINET S100VQUM
Period2024-10-01 → 2025-03-31
Filed2025-05-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.3bn | 2024-10-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥14.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.9bn | 2023-10-01 → 2024-03-31 | Cons. | Net sales |
| Operating income | ¥629m | 2024-10-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥836m | 2023-10-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥654m | 2024-10-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥831m | 2023-10-01 → 2024-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥654m | 2024-10-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥550m | 2023-10-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥427m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.5bn | 2023-10-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥199m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥427m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥213m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥14.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥15.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥14.9bn | at 2024-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.0bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥6.1bn | at 2024-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥9.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.5bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥8.7bn | at 2024-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.2bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2023-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥149m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥807m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥93m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥360m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥378m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥19.65 | 2024-10-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.26 | 2023-10-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.18 | 2023-10-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 66.1% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 43
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2024-10-01 → 2025-03-31 | ¥123m |
| Otherother segments | revenue external | 2024-10-01 → 2025-03-31 | ¥123m |
| Otherother segments | segment profit | 2024-10-01 → 2025-03-31 | −¥6m |
| Reconciling Itemsreconciling | revenue | 2024-10-01 → 2025-03-31 | −¥74m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-10-01 → 2025-03-31 | −¥74m |
| Reconciling Itemsreconciling | segment profit | 2024-10-01 → 2025-03-31 | −¥683m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥2m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥964m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥4.1bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥4.1bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥72m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥393m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥166m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥166m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2024-10-01 → 2025-03-31 | −¥38m |
| —segment total | revenue | 2024-10-01 → 2025-03-31 | ¥6.3bn |
| —segment total | revenue external | 2024-10-01 → 2025-03-31 | ¥6.2bn |
| —segment total | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥74m |
| —segment total | segment profit | 2024-10-01 → 2025-03-31 | ¥1.3bn |
| Otherother segments | revenue | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| Otherother segments | revenue external | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| Otherother segments | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥419,000 |
| Otherother segments | segment profit | 2023-10-01 → 2024-03-31 | ¥159m |
| Reconciling Itemsreconciling | revenue | 2023-10-01 → 2024-03-31 | −¥23m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-10-01 → 2024-03-31 | −¥23m |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-03-31 | −¥679m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥13m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥967m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥4.4bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥4.4bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥10m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥520m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | −¥131m |
| —segment total | revenue | 2023-10-01 → 2024-03-31 | ¥6.7bn |
| —segment total | revenue external | 2023-10-01 → 2024-03-31 | ¥6.6bn |
| —segment total | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥23m |
| —segment total | segment profit | 2023-10-01 → 2024-03-31 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 515
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 1949300 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0897 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 1250000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0575 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 900000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0414 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 551200 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0254 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 524000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0241 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 324434 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0149 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 220000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0101 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 202500 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0093 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 201482 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0093 | |
| Number of shares held | CurrentQuarterInstant | 11438406 | |
| Shareholding ratio | CurrentQuarterInstant | 0.5264 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 281000 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 21700600 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 217006 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 28730 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 22010330 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 217006 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 281000 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 281000 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.013 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 281000 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 281000 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.013 | |
| Cash and deposits | Prior1YearInstant | 7280009000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 7161525000 | JPY |
| Notes and accounts receivable trade and contract assets | Prior1YearInstant | 2648055000 | JPY |
| Notes and accounts receivable trade and contract assets | CurrentQuarterInstant | 2412293000 | JPY |
| Work in process | Prior1YearInstant | 19751000 | JPY |
| Work in process | CurrentQuarterInstant | 18051000 | JPY |
| Other ca | Prior1YearInstant | 417640000 | JPY |
| Other ca | CurrentQuarterInstant | 305633000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -6729000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -4199000 | JPY |
| Current assets | Prior1YearInstant | 10358728000 | JPY |
| Current assets | CurrentQuarterInstant | 9893304000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |